Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings

CONCLUSIONS: These data suggest approaches to increase persistence and adherence to PCSK9i mAb and ezetimibe should be implemented prior to or within 182 days following treatment initiation.PMID:38691317 | DOI:10.1007/s12325-024-02868-z

Source: Adv Data - May 1, 2024 Category: Epidemiology Authors: Paul Muntner Lama Ghazi Jenna Jones Nafeesa Dhalwani Bharat Poudel Ying Wen Ligong Chen Zhixin Wang Vera Bittner Bethany Kalich Michael E Farkouh Mark Woodward Lisandro D Colantonio Robert S Rosenson Source Type: research